Evidence map›Paper›PMID 41035551›Full record

ArticleBulletin of the World Health Organization2025

Parkinson disease treatments on national essential medicines lists, African Region.

Natasha Fothergill-Misbah, Rodrigo Cataldi, Mark Stothard, Neerja Chowdhary, Njideka Okubadejo, Bernadette Cappello, Richard Walker, Tarun Dua

Abstract read
In one paragraph

Article in Bulletin of the World Health Organization, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Natasha Fothergill-MisbahPopulation Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England.
Rodrigo CataldiDepartment of Mental Health, Brain Health and Substance Use, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland.
Mark StothardNorthumbria Healthcare NHS Foundation Trust, North Shields, England.
Neerja ChowdharyDepartment of Mental Health, Brain Health and Substance Use, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland.
Njideka OkubadejoCollege of Medicine, University of Lagos, Lagos, Nigeria.
Bernadette CappelloDepartment of Health Products Policy and Standards, World Health Organization, Geneva, Switzerland.
Richard WalkerNorthumbria Healthcare NHS Foundation Trust, North Shields, England.
Tarun DuaDepartment of Mental Health, Brain Health and Substance Use, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland.

Funding

World Health Organization 001
6 · The paper itself

Abstract

The prevalence of Parkinson disease is increasing globally. Despite the existence of effective and affordable medicines for Parkinson disease, access to these medicines is limited in the World Health Organization (WHO) African Region. Several factors influence accessibility, including lack of prioritization of Parkinson disease, shortage of a trained health workforce, barriers to health financing and lack of inclusion of medicines in national essential medicines lists. We determined alignment of the most recent national essential medicines lists of 47 countries in the WHO African Region with the 23rd edition of the

Indexed as

Antiparkinson AgentsDrugs, EssentialParkinson DiseaseAfricaHealth Services AccessibilityHumansWorld Health OrganizationAntiparkinson AgentsDrugs, Essential

Identifiers

PMID41035551
PMCPMC12481222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.